Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
17AAG in Patients With Von Hippel Lindau Disease and Renal Tumors
NCT00088374Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2004
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tanespimycin in von Hippel–Lindau disease (VHL) and kidney cancer, sponsored by National Cancer Institute. Primary endpoint: Number of Participants With a Renal Tumor Response at 12 weeks. Started Jul 2004; status: completed.
02
Drugs
tanespimycin
03
Conditions
von Hippel–Lindau disease (VHL)kidney cancer
Beyond the preview
Go deeper on NCT00088374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088374.